Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.57 |
| ▸ | KDR | P35968 | 6/20 | 0.57 |
| ▸ | PAK1 | Q13153 | 7/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3710491 | 0.93 | PAK1 (0.57) | EGFRFGFR1KDRPAK1PIK3CA | |
| SCHEMBL298470 | 0.92 | PIK3CA (0.50) | EGFRFGFR1KDRPAK1PIK3CA | |
| SCHEMBL297367 | 0.90 | ALK (0.48) | EGFRFGFR1KDRPAK1PIK3CA | |
| SCHEMBL297385 | 0.89 | CYP3A4 (0.51) | EGFRFGFR1KDRPAK1PIK3CA | |
| SCHEMBL298351 | 0.88 | PIK3CA (0.49) | EGFRFGFR1KDRPAK1PIK3CA | |
| SCHEMBL299321 | 0.88 | PAK1 (0.45) | EGFRFGFR1KDRPAK1PIK3CA | |
| SCHEMBL298341 | 0.86 | ALK (0.51) | EGFRFGFR1KDRPAK1PIK3CA | |
| SCHEMBL298085 | 0.84 | CYP19A1 (0.49) | EGFRFGFR1KDRPAK1PIK3CA | |
| SCHEMBL298434 | 0.84 | PAK1 (0.56) | PAK1ALKPAK4 | |
| SCHEMBL298196 | 0.84 | PAK1 (0.44) | EGFRFGFR1KDRPAK1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | EGFR 195/4885FGFR1 129/4885KDR 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.